Looking to add somewhere around this 9.54 area. Let's see how well it holds there and if the market can turn around.

I'm still holding a core position in it. I still like the momentum, held up great in this choppy market. Just broke bull flag on daily, excellent volume, last bull flag break had a 3 point move. About 2 more weeks left in the weekly squeeze. It took 5 weeks for it to break resistance at 9.54, picked up some there , next resistance is around the 10.60 area. Not saying it's gonna get there, JMO!!! ADX is 35, strong trend in place. I really like trading stocks like this.

Owned it for a while now...Looking to add more on a close above 9.54

Any Thoughts on This...

Bruce Jackson of Lake Street assumes coverage of Aratana Therapeutics Inc (NASDAQ: PETX) with a Buy rating and $15 target price, saying twelve additional new products in the pipeline suggest the revenue growth can continue for the next several years. The analyst expects more than $200 million in peak sales potential from Galliprant, Nocita and Entyce.

Market Opportunities

Jackson said Galliprant, for the control of pain and inflammation associated with osteoarthritis in dogs, offers a market opportunity in excess of $100 million . Nocita, a liposomal bupivacaine product for post-op pain management, could achieve peak sales well over $75 million."Entyce, which we view as an underappreciated asset positioned to emerge as a breakthrough first-in-class therapy for appetite stimulation, could surprise with peak sales potential in excess of $100 million ," Jackson wrote in a note.

Jackson projects Aratana's current target market of $2 billion to increase to more than $5 billion over the next ten years. The analyst expects Aratana to achieve fully-taxed, adjusted EPS of $1.92 , excluding milestone payments from Elanco, in 2021.

Catalysts For The Drugs

Meanwhile, the upcoming catalysts include the start of pivotal field effectiveness trials for cat formulations of Nocita and Entyce in late 2016, followed by conditional licensure for AT-014 in late 2016 or early 2017. Further, the EMA approval of Galliprant is anticipated in early-2017.
At time of writing, shares of Aratana rose 3.18 percent to $9.09 . The price target of $15 represents a potential upside of 70 percent from Friday's close.

So goes IBB, so goes ARIA...Like a hand and glove!

13000, 18 NOV 16 11 Calls, bought on offer today...NICE!

Big Call buyer on the Sep 23/7.5 Calls today.

Nice buy today on the Sep 2 10/Call Weekly options. Looks like Someone is expecting a move this week.

Here's some news from last week. Holding, wait and see. GLTU ALL!

0709 GMT Sanofi will keep looking for potential acquisition targets after it lost a bidding war for Medivation to rival Pfizer, says Bryan Garnier . "Obviously, the company won't call it a day and will continue to look for other potential targets in the field (and preferably profitable ones, with a promising development pipeline)," it says. Bryan Garnier says Regeneron, Incyte , Ariad or BioMarin are potential targets. It rates the shares at neutral with a target price at EUR83 . Shares little changed at EUR69.55 .

Great earnings, big open interest keeping it from moving up today. Get pass expiration friday today and expect fire works next week...IMO

BINGO...Great ride!!!

Big spread today, somebody bought 20,000 19 AUG 16 6C and help pay for them by selling 20,000 19 AUG 16 5P. Very bullish !!!

Check out the option activity on the Jul 29 6 Calls over 52000 traded with O/I only 20. Somebody is expecting something good here soon. I know there's been some talk of merging the Steel companies.

Sad Thing Is ...You get a Law firm saying that they are investigating a company, it can really damage a stock without any penalty what so ever for the firm. Most of the time they find no wrong doing but the damage has already been done. I wonder if it's just another way of keeping the PPS in check. JMO

Thanks for the reply. Unreal volume!!!

Hi all, I had a question about the volume on 07/01/16. TOS had total volume at 1,505,947,300. Hard to believe when the price had zero movement.

Is EXAS Eyeing 17.00, Sure look like it.

http://tinyurl.com/z6no59u

I am new to IHUB Beandog, don't know how it being my first post here is strange. Enlighten me! I was just asking a question?

One acct I had 5000 shares, dropped to 357. seems like they are worth less to me.

Man that 1/14 split, feel like I got the short end of the stick on that one.Does it suppose to even out somewhere along the line?